Determinants of beneficial effect of mineralocorticoid receptor antagonism on exercise capacity in heart failure with reduced ejection fraction.

CONCLUSIONS: In patients with HFrEF, improvement in exercise capacity in response to the addition of spironolactone to treatment is more evident in the presence of diabetes, decreased renal function and lower BNP, and improvement in GLS is a contributor to this beneficial effect of MRA.
PMID: 29862486 [PubMed - as supplied by publisher]

Source: Polish Heart Journal - June 4, 2018 Category: Cardiology Authors: Dankowski R, Kotwica T, Szyszka A, Przewłocka-Kosmala M, Sacharczuk W, Karolko B, Kobusiak-Prokopowicz M, Mysiak A, Kosmala W Tags: Kardiol Pol Source Type: research